Analysis of the Association of Matrix Metalloproteinase-1 Gene Promoter (rs1799750) Polymorphism and Risk of Ovarian Cancer.
Studies investigating the association between matrix metalloproteinase-1 (MMP1) gene promoter 1607-base pair (bp) polymorphism and ovarian cancer risk have yielded conflicting results. We therefore carried out a meta-analysis of 754 ovarian cancer cases and 1184 controls from 5 published case-control studies. The strength of the association between MMP1 1607-bp polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). The results suggest that no statistically significant associations exist between MMP1 1607-bp polymorphisms and ovarian cancer risk in all 4 genetic models (2G2G vs 1G1G: OR, 1.08; 95% CI, 0.81-1.43; P = 0.23; 1G2G vs 1G1G: OR, 1.06; 95% CI, 0.82-1.36; P = 0.15; 1G2G + 2G2G vs 1G1G: OR, 1.05; 95% CI, 0.83-1.34; P = 0.16; 2G2G vs 1G1G + 1G2G: OR, 0.98; 95% CI, 0.80-1.20; P = 0.84). In summary, this meta-analysis showed that the MMP1 1607-bp polymorphism is not associated with ovarian cancer risk.